Indacaterol

• COPD Maintenance Treatment
• Chronic Bronchitis
• Emphysema
• Long-Acting Bronchodilator Therapy

Indacaterol is an ultra-long-acting beta-2 adrenergic agonist (LABA) bronchodilator used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). This inhaled medication provides 24-hour bronchodilation with once-daily dosing, offering convenience and sustained symptom control.

Mechanism of Action

Indacaterol is a selective beta-2 adrenergic receptor agonist with rapid onset and long duration of action. When inhaled, it binds to beta-2 receptors on airway smooth muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP levels. This leads to relaxation of bronchial smooth muscle and bronchodilation. Indacaterol's long duration of action (24 hours) is due to its high affinity for lipid rafts in the cell membrane, providing a depot effect with gradual release to receptors. The rapid onset (approximately 5 minutes) is attributed to its moderate lipophilicity, allowing quick access to receptor binding sites.

Available Formulations

Indacaterol is available as dry powder capsules for oral inhalation using the Neohaler device. As monotherapy (Arcapta Neohaler), it is available in 75 mcg capsules. It is also available in fixed-dose combinations with glycopyrrolate (Utibron Neohaler) and with mometasone and glycopyrrolate (Enerzair Breezhaler). The capsules are for inhalation only and should not be swallowed.

Medical Uses

Indacaterol is FDA-approved for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not indicated for the relief of acute bronchospasm, for asthma (as monotherapy), or for acute deteriorations of COPD. Clinical trials demonstrated significant improvements in trough FEV1, COPD symptoms, and quality of life.

Dosing Guidelines

The recommended dose is one 75 mcg capsule inhaled once daily using the Neohaler inhaler device. The capsule should be used immediately before inhalation and should not be stored in the device. Only use the inhaler provided with the product. If a dose is missed, take it as soon as possible; do not take more than one dose per day. No dose adjustment is required for renal or hepatic impairment.

Important Safety Information

Indacaterol carries a boxed warning that LABAs increase the risk of asthma-related death; it is not indicated for asthma. LABA monotherapy in asthma without a concomitant inhaled corticosteroid is contraindicated. For COPD, indacaterol should not be used for acute bronchospasm (use a rescue inhaler). Paradoxical bronchospasm may occur; discontinue if this occurs. Cardiovascular effects (tachycardia, hypertension, QT prolongation) may occur. Hypokalemia and hyperglycemia can occur.

Drug Interactions

Beta-blockers may diminish the bronchodilatory effect of indacaterol; use selective beta-1 blockers with caution if needed. MAO inhibitors and tricyclic antidepressants may potentiate cardiovascular effects. Concomitant use with other adrenergic drugs may potentiate adverse effects. QT-prolonging medications should be used with caution. Diuretics may potentiate hypokalemia. No significant CYP450 interactions occur at clinically relevant concentrations.

Special Populations

There are no adequate studies in pregnant women. Beta-agonists may interfere with uterine contractility during labor. Use during pregnancy only if clearly needed. It is unknown whether indacaterol is excreted in human breast milk; use with caution. Safety and efficacy have not been established in pediatric patients; indacaterol is not indicated for asthma in children. Elderly patients do not require dose adjustment. No dose adjustment is needed for mild to moderate renal impairment; severe impairment has not been studied. No dose adjustment is needed for mild to moderate hepatic impairment; severe impairment has not been studied.